For companies: explore licensing operational data for AI. Check eligibility

Biotech Investment Analyst — Drug Asset & Company Assessment

$120–$200/hr

Apply on Mercor →

New to Mercor? before applying.

Get new roles by emailFollow on X

Jobs › Science & Research › Mercor

Pay
$120 to $200 per hour
Pay type
Hourly
Platform
Mercor
Field
Science & Research
Where
Remote
First seen
Posted
History
Half of Mercor roles listed since Oct 2 were gone within 28 days (of 329). How long roles stay open
Feed read

This listing comes from Mercor's own public job feed. The posting on Mercor is the source of truth.

About the role

Mercor is partnering with a biotech and pharma research team on expert human-evaluation work — creating and critiquing rubrics that analyze commercial drugs and drug-development programs. We're seeking a biotech investment analyst (specialist-fund background) for a paid pilot, with the potential to continue as the work scales.

Responsibilities

  • Create and critique rubrics that analyze commercial drugs and drug-development programs
  • Provide overall company and asset assessment — mechanism, clinical data, competitive position, and value drivers
  • Judge the quality of an investment-style thesis and flag weak, overconfident, or missing assumptions
  • Apply your assessment across the pilot's set of companies (~5–10)

Requirements

  • US-based biotech / healthcare investment analyst with a specialist-fund background
  • Familiarity with biotech/pharma development programs
  • Able to assess a drug asset and the company behind it end-to-end
  • 5+ years evaluating biotech/pharma companies or assets

Engagement Details

  • Duration: Approximately 10–20 hours over a 1–2 week pilot
  • Remote — US-based

Why Participate

  • Help improve expert AI evaluation of drugs and drug-development programs
  • Recurring engagement for strong contributors

More: Every role for scientists · Every role that lists $100+ an hour · How Mercor pays, in its own words · What AI training roles pay · Free resume help